Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts

@article{Locatelli2013PerifosineAS,
  title={Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts},
  author={S. Locatelli and A. Giacomini and A. Guidetti and L. Cleris and R. Mortarini and A. Anichini and A. M. Gianni and C. Carlo-Stella},
  journal={Leukemia},
  year={2013},
  volume={27},
  pages={1677-1687}
}
The effects of the Akt inhibitor perifosine and the RAF/MEK/ERK inhibitor sorafenib were investigated using two CD30+Hodgkin lymphoma cell lines (L-540 and HDLM-2) and the CD30−HD-MyZ histiocytic cell line. The combined perifosine/sorafenib treatment significantly inhibited mitogen-activated protein kinase and Akt phosphorylation in two of the three cell lines. Profiling of the responsive cell lines revealed that perifosine/sorafenib decreased the amplitude of transcriptional signatures that… Expand
BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts
TLDR
Gene expression profiling indicated that the synergistic effects of Givinostat/Sorafenib treatment are associated with the modulation of cell cycle and cell death pathways, and Knockdown experiments identified BIM as a key signaling molecule that mediates Giv inostat /SorAFenib-induced oxidative death of HL cells. Expand
Sorafenib inhibited cell growth through the MEK/ERK signaling pathway in acute promyelocytic leukemia cells
TLDR
Sorafenib may inhibit proliferation and induce cell cycle arrest and apoptosis in APL cells and the underlying mechanisms of such effects may be associated with alterations to the expression of apoptosis-associated and cell cycle-associated molecules via MEK/ERK signaling pathway inhibition. Expand
Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation
TLDR
Gene expression analysis indicated that the effects of AEZS-136 were associated with the modulation of cell cycle and cell death pathways, and dual PI3K/ERK inhibition might be an effective approach for improving therapeutic outcomes in HL. Expand
Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells
TLDR
The results show that apoptotic cell death induced by sorafenib in bladder cancer cells is dependent on cathepsin B activity and involved PTEN and Akt signaling pathways. Expand
Dual PI 3 K / ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER 3 downregulation
PI3K/AKT and RAF/MEK/ERK pathways are constitutively activated in Hodgkin lymphoma (HL) patients, thus representing attractive therapeutic targets. Here we report that the PI3K/ERK dual inhibitorExpand
Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34+ cells
TLDR
The Akt inhibitor perifosine induces in vivo DR5 expression on TECs, thereby overcoming tumor resistance to the vascular disruption activity of CD34−TRAIL+ cells and highlighting a strategy to rescue patients with primary or acquired resistance due to the lack ofDR5 expression in tumor vasculature. Expand
Sorafenib/Regorafenib and Phosphatidyl Inositol 3 Kinase/Thymoma Viral Proto-Oncogene Inhibition Interact to Kill Tumor Cells
TLDR
It is demonstrated that the combination of sorafenib family kinase inhibitors with inhibitors of the PI3K/AKT pathway kills tumor cells in vitro and in vivo. Expand
Constitutive localization of DR4 in lipid rafts is mandatory for TRAIL-induced apoptosis in B-cell hematologic malignancies
TLDR
Results provide a key mechanism for TRAIL sensitivity in B-cell malignances: the association, within lipid microdomains, of DR4 but not DR5, with a specific ganglioside, that is the monosialogangliosides GM3. Expand
Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors
TLDR
The potential of MALDI-MSI to predict the efficacy of unlabelled small molecule antiangiogenic drugs in malignant tissue is demonstrated, demonstrating that primary resistance to angiogenesis inhibitors involves limited tumor tissue drug penetration. Expand
Sequence-dependent effect of sorafenib in combination with natural phenolic compounds on hepatic cancer cells and the possible mechanism of action
TLDR
Concomitant treatment with Sora and Cur or Kmf appears to be a potent and promising therapeutic approach that may control hepatic cancer by triggering cell cycle arrest and apoptosis. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 59 REFERENCES
Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways
TLDR
The effects of combining perifosine with the commonly used chemotherapy drug etoposide with a specific activation of the caspase-dependent Fas death receptor pathway caused an increase in cell death in cultured human Jurkat T-leukemia cells. Expand
Perifosine induces differentiation and cell death in prostate cancer cells.
TLDR
Findings indicate that perifosine induces GSK-3beta-related differentiation and caspase-independent cell death in prostate cancer PC-3 cells and identifies specific biomarkers for perifOSine therapy. Expand
Sorafenib and Vorinostat Kill Colon Cancer Cells by CD95-Dependent and -Independent Mechanisms
TLDR
Treatment of colon cancer cells with sorafenib + vorinostat activates CD95 via de novo ceramide synthesis that promotes viability via autophagy or degrades survival via either the extrinsic or intrinsic pathways. Expand
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
TLDR
Coadministration of HDACIs with perifosine in human leukemia cells leads to Akt and MEK/ERK disruption, a marked increase in ceramide and ROS production, and a striking increase in mitochondrial injury and apoptosis, which raises the possibility that combining these agents may represent a novel antileukemic strategy. Expand
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism
TLDR
The findings indicate that perifosine is a promising therapeutic agent for treatment of T-ALL cases characterized by both upregulation of the PI3K/Akt survival pathway and overexpression of P-gp. Expand
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
TLDR
The data provide the rationale for clinical trials of perifosine to improve patient outcome in MM and demonstrate significant antitumor activity in a human plasmacytoma mouse model associated with down-regulation of Akt phosphorylation in tumor cells. Expand
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells
TLDR
The data suggest that premexetred and sorafenib act synergistically to enhance tumor killing via the promotion of a toxic form of autophagy that leads to activation of the intrinsic apoptosis pathway, and predict that combination treatment represents a future therapeutic option in the treatment of solid tumors. Expand
Perifosine as a Potential Novel Anti-Cancer Agent Inhibits EGFR/MET-AKT Axis in Malignant Pleural Mesothelioma
TLDR
A novel mechanism of action of perifosine is provided, directly inhibiting EGFR/MET-AKT1/3 axis, providing a rationale for a novel translational approach to the treatment of MMe. Expand
The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice.
TLDR
Data show that 1D09C3 exerts a potent antitumor effect by activating ROS-dependent, JNK-driven cell death, cures the great majority of mice treated at an early-stage of disease, and significantly prolongs survival of mice with advanced-stage disease. Expand
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
TLDR
The data suggest that premexetred and sorafenib act synergistically to enhance tumor killing via the promotion of a toxic form of autophagy that leads to activation of the intrinsic apoptosis pathway, and predict that combination treatment represents a future therapeutic option in the treatment of solid tumors. Expand
...
1
2
3
4
5
...